Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 36Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 11Neoplasms 9Neoplasm Metastasis 9Sarcoma 4Lung Neoplasms 4Esophageal Neoplasms 4Adenocarcinoma 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Melanoma 3Breast Neoplasms, Male 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Pancreatic Diseases 2Metastatic Pancreatic Adenocarcinoma 2Carcinoma 2Advanced Solid Tumor 2Tongue Neoplasms 1Thymus Neoplasms 1Solid Cancer 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic cancer, adult 1Ovarian Neoplasms 1

Interventions

Gemcitabine 3Taxes 1SLC-0111 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Metastatic Pancreatic Ductal Adenocarcinoma × Albumin-Bound Paclitaxel × Clear all
NCT06904378 2026-05-19

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Washington University School of Medicine

Phase 1/2 Recruiting
61 enrolled
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡